XML 15 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 30, 2018
Dec. 29, 2017
 [1]
Current assets:    
Cash and cash equivalents $ 232,331 $ 183,164
Short-term investments 194,589 204,607
Short-term restricted cash and investments 504 504
Trade and other receivables 91,999 81,192
Inventory, net 7,563 6,657
Unbilled collaboration revenue 31,844 0
Prepaid expenses and other current assets 6,850 8,750
Total current assets 565,680 484,874
Long-term investments 96,710 64,255
Long-term restricted cash and investments 1,500 4,646
Property and equipment, net 45,412 25,743
Goodwill 63,684 63,684
Other long-term assets 1,929 12,092
Total assets 774,915 655,294
Current liabilities:    
Accounts payable 11,078 9,575
Accrued compensation and benefits 20,756 21,073
Accrued clinical trial liabilities 15,351 19,849
Accrued collaboration liabilities 7,974 8,974
Rebates and fees due to customers 11,989 7,565
Current portion of deferred revenue 0 31,984
Other current liabilities 17,711 16,150
Total current liabilities 84,859 115,170
Long-term portion of deferred revenue 3,177 238,520
Other long-term liabilities 17,113 16,643
Total liabilities 105,149 370,333
Commitments (Note 11)
Stockholders’ equity    
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 295,700,576 and 289,923,798 at September 30, 2017 and December 31, 2016, respectively 297 296
Additional paid-in capital 2,125,166 2,114,184
Accumulated other comprehensive loss (887) (347)
Accumulated deficit (1,454,810) (1,829,172)
Total stockholders’ equity 669,766 284,961
Total liabilities and stockholders’ equity $ 774,915 $ 655,294
[1] The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.